JMP Securities Reiterates “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research report issued on Tuesday,Benzinga reports. They presently have a $21.00 price objective on the biotechnology company’s stock, down from their prior price objective of $22.00. JMP Securities’ target price indicates a potential upside of 137.83% from the company’s previous close.

Several other research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. decreased their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Trading Up 3.2 %

Enanta Pharmaceuticals stock opened at $8.83 on Tuesday. Enanta Pharmaceuticals has a 1-year low of $8.00 and a 1-year high of $17.80. The firm has a market capitalization of $187.11 million, a PE ratio of -1.61 and a beta of 0.56. The firm’s 50 day simple moving average is $10.92 and its 200 day simple moving average is $12.30.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Institutional investors have recently modified their holdings of the company. State Board of Administration of Florida Retirement System bought a new position in Enanta Pharmaceuticals during the first quarter valued at approximately $118,000. Vanguard Group Inc. raised its position in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares during the period. Virtu Financial LLC bought a new stake in Enanta Pharmaceuticals in the first quarter worth $191,000. Farallon Capital Management LLC boosted its position in Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after buying an additional 70,000 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Enanta Pharmaceuticals by 13.3% during the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after buying an additional 8,645 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.